Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12059692 | 0.94 | HTR2A (0.33) | KCNH2CYP2D6KDM4EHTR2A | |
| SCHEMBL22570149 | 0.94 | HTR2A (0.33) | KCNH2CYP2D6KDM4EHTR2A | |
| SCHEMBL27014297 | 0.85 | KCNH2 (0.39) | KCNH2KDM4E | |
| SCHEMBL23222402 | 0.81 | KDM4E (0.37) | KDM4E | |
| SCHEMBL21191622 | 0.80 | HTR2A (0.33) | KCNH2KDM4EHTR2A | |
| SCHEMBL10129028 | 0.79 | SSTR4 (0.36) | SSTR4KCNH2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL14092960 | 0.79 | SSTR4 (0.36) | SSTR4KCNH2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL8759751 | 0.78 | KDM4E (0.38) | KDM4E | |
| SCHEMBL13930780 | 0.78 | SLC6A1 (0.32) | SSTR4KCNH2CYP2D6KDM4EHTR2A | |
| SCHEMBL21191562 | 0.77 | HTR2A (0.37) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295113-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD | 2023-09-21 | — | — | US | disclosed |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | CELGENE CORPORATION (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORPORATION | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | SSTR4 4775/4885KCNH2 1015/4885CYP2D6 2953/4885 |
| US-20230295113-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | SSTR4 4733/4885KCNH2 3950/4885CYP2D6 3524/4885 |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | RIPK2, RIPK1, RIPK4 | SSTR4 4775/4885KCNH2 1015/4885CYP2D6 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.